Objectives: To assess the risk factors for increased antimicrobial resistance among Enterobacteriaceae representing the most common biliary pathogens.
Introduction
Acute cholangitis is an infection of the biliary tract with various clinical courses ranging from a mild form, characterized by fever and/or chills, abdominal pain and jaundice, to life-threatening septic shock. 1 The biliary tract is usually sterile in humans. 2 -4 The continuous flow of bile, the bacteriostatic effects of bile salts, anatomical barriers such as the sphincter of Oddi and potent immunological defence mechanisms protect the biliary system from bacterial invasion. 5 In general, microbial colonization of the biliary tract occurs in association with bile duct obstruction, which leads to increased intrabiliary pressure and a decrease in bile flow. 5, 6 Early biliary decompression by endoscopic or percutaneous transhepatic approaches and appropriate empirical antibiotic therapy are the main elements of successful treatment. 7 -10 The group of Enterobacteriaceae including Escherichia coli, Klebsiella spp., Citrobacter spp., Proteus spp. and Enterobacter spp. represents the predominant biliary pathogens possessing high pathogenic potential. Therefore, these species are often involved in severe sepsis or septic shock. 11 -14 Consequently, Enterobacteriaceae must be adequately covered by empirical antimicrobial treatment. However, the extensive use of broad-spectrum antibiotics in previous years has promoted antibiotic resistance among Enterobacteriaceae, and empirical antimicrobial treatment has become a therapeutic challenge. 15, 16 For that reason, it is essential to consider the risk factors for increased antimicrobial resistance in acute bacterial cholangitis.
In the current study, the resistance patterns of Enterobacteriaceae were analysed and related to age, sex, prior antibiotic treatment, the genesis of the cholangitis and the type and number of previous interventional procedures [percutaneous transhepatic cholangiography (PTC)/endoscopic retrograde cholangiography (ERC)].
Patients and methods

Study population
The study included 276 patients with acute cholangitis who were treated between April 1996 and May 2009 at the II. Medizinische Klinik und Poliklinik, Klinikum Rechts der Isar, Technische Universitä t Mü nchen. The Ethics Committee of the hospital approved this study. First, our clinical endoscopic database was queried for patients who had undergone an ERC or a PTC. The clinical indications for the endoscopic or percutaneous procedures were then clarified by analysing the patients' records.
Patients were eligible for inclusion in the study if all of the following criteria were fulfilled: a diagnosis of acute cholangitis with a typical clinical presentation: (i) fever (temperature .388C) and/or elevated parameters of infection (leucocytes .12000/mL and/or C-reactive protein .30 mg/L); (ii) elevated parameters of cholestasis reaching at least certain levels (1.5 times the upper limit of the normal range for bilirubin and/or 2.5 times the upper limit of the normal range for g-glutamyltransferase and/or 2.5 times the upper limit of the normal range for alkaline phosphatase); (iii) positive microbiology (blood and/or bile cultures) with antimicrobial susceptibility testing; and (iv) no focus of infection other than acute cholangitis.
Exclusion criteria were as follows: (i) biliary pancreatitis; (ii) end-stage liver cirrhosis; and (iii) incomplete patient records.
Antibiotic treatment within the last 6 months prior to the onset of cholangitis was assessed by analysing the patients' records.
Isolation of bacteria
Bile was obtained by endoscopic retrograde or percutaneous transhepatic biliary access. ERC was performed with a standard Olympus TFJ 160-R videoduodenoscope. Endoscopic sphincterotomy was conducted using an Olympus papillotome introduced over a Terumo guidewire. Intraductal bile was collected before injection of the contrast agent by passing a sterile standard ERC catheter into the obstructed bile duct and aspirating bile into a sterile 10 mL syringe. In the case of percutaneous transhepatic biliary drainage (PTBD), 2 -4 mL of bile was collected into a sterile 10 mL syringe after penetration of the bile duct with the puncture needle. Thereafter, a PTBD was inserted using the Seldinger technique.
Microbiological investigation
Blood culture
A volume of 20 mL of venous blood was obtained from patients who had had febrile episodes, and was inoculated into an aerobic and an anaerobic blood culture bottle (BacTec system, Becton Dickinson, Heidelberg, Germany). At the Institute of Microbiology, blood cultures were placed in an automated microbiology growth and detection system (BACTEC system, Becton Dickinson, Heidelberg, Germany) and incubated at 378C for 5 days.
Bile culture
The bile specimens were examined for aerobic and anaerobic bacteria. In each case, 50 -100 mL of bile was transferred into liquid nutrient media (glucose broth and thioglycollate broth) and onto solid culture media (Columbia sheep blood agar, chocolate agar, MacConkey agar, Schaedler anaerobic agar, Schaedler KV anaerobic agar and Sabouraud agar). Subsequently, the culture media were incubated at 378C. The aerobic cultures were incubated for 48 h, with the first readout taken after 24 h. The anaerobic cultures were monitored for the first time after 48 h and processed further as required.
Microbial identification and antibiotic susceptibility testing
From April 1996 to December 2006, microbial identification was conducted using biochemical testing systems (ATB, API and VITEK system, bioMérieux, Nü rtingen, Germany). From 2007 onwards, matrix-associated laser desorption/ionization-time of flight (MALDI-TOF, Bruker Corporation, Billerica, USA) was mainly used for microbial identification. Antimicrobial susceptibility assessment was performed using an automated microdilution system (VITEK system, bioMérieux, Nü rtingen, Germany) or standardized discs. Throughout the study, antimicrobial susceptibility testing was performed according to CLSI methodologies, and testing was regularly updated to the latest recommendations. The resistance patterns were analysed with particular consideration of intrinsic resistance. Therefore, strains with intrinsic resistance towards the analysed antimicrobial agent were excluded from the analysis. 17 
Statistical analysis
The descriptive statistics relating to patients' characteristics are provided in absolute and relative frequencies for categorical data, and medians and ranges for continuous data. Explorative analyses were performed using generalized estimation equations (GEEs) with an exchangeable working correlation matrix to account for repeated measurements in subjects. Univariate and multivariate GEE models were used to compute ORs with corresponding 95% CIs for the binomial outcomes. All statistical tests, conducted using the GEE models, were performed in an explorative manner with a 5% significance level. To avoid confounding, variables carrying similar information were not simultaneously included in the multivariate model. This applied to the variables 'stent therapy' and 'antimicrobial pre-treatment'.
Results
In total, 461 Enterobacteriaceae were identified from 276 patients with 309 episodes of cholangitis. The median age of the patients was 68 years (range 29-93 years). In addition, 115 patients had a benign cause for their cholangitis, 144 patients had a malignant cause and 17 patients had an idiopathic cause (Table 1) . ERC was performed in 123 patients, and PTC was performed in 56 patients. Ninety-seven patients had not undergone previous PTC/ERC prior to bile collection. Stent therapy was performed in 141 patients at the time of bile collection. E. coli (193; 42%) was the predominant species among the group of Enterobacteriaceae, followed by Klebsiella species (156; 34%) and other Enterobacteriaceae (112; 24%), including the genera Enterobacter, Citrobacter, Proteus and Serratia. The overall susceptibility rates of Enterobacteriaceae to ampicillin, ampicillin/ sulbactam, ceftriaxone, ciprofloxacin/ofloxacin and co-trimoxazole were 40%, 53%, 90%, 85% and 81%, respectively (Table 2) .
In the univariate analysis (Table 3) , Enterobacteriaceae from patients who had undergone stent therapy were significantly less susceptible to quinolones (184/239 versus 205/221; P,0.001) and ceftriaxone (208/239 versus 209/222; P ¼ 0.014) compared with patients who had not received stent therapy. The multivariate analysis (Table 4 ) also revealed a decrease in antimicrobial susceptibility to ceftriaxone (P ¼0.039) and quinolones (P¼ 0.056). Patients who had undergone stent therapy had 4-fold higher odds [0.24; (95% CI 0.06-0.93)] of acquiring ceftriaxone-resistant Enterobacteriaceae compared with patients who had not undergone stent therapy.
Furthermore, the number of interventional procedures (ERC/ PTC) was associated with a decrease in antimicrobial susceptibility. The odds for susceptibility to ampicillin, ampicillin/sulbactam, ceftriaxone, quinolones (ciprofloxacin/ofloxacin) and co-trimoxazole decreased by 2% (P ¼ 0.280), 2% (P ¼0.069), 4% (P ¼ 0.035), 6% (P,0.001) and 3% (P ¼ 0.003), respectively, per interventional procedure (PTC/ERC) ( Figure 1 and Table 5 ).
There was also a significant correlation between previous antimicrobial treatment and decreased antimicrobial susceptibility (Table 3) to ampicillin (P ¼ 0.028), ceftriaxone (P,0.001), ciprofloxacin/ofloxacin (P,0.001) and co-trimoxazole (P ¼ 0.002). As illustrated in Table 6 , patients who had received stent therapy received significantly more antimicrobial treatment within the 6 months prior to the onset of cholangitis compared with patients who had not received stent therapy (P,0.001).
Univariate analyses also indicated that patients with a benign cause of cholangitis had a significantly higher susceptibility to quinolones (ciprofloxacin/ofloxacin) (161/182 versus 199/248; P ¼ 0.048) than patients with malignant underlying disease. However, the multivariate analysis revealed that the genesis of the cholangitis was not an independent risk factor for increased antimicrobial resistance for ciprofloxacin/ofloxacin (P ¼0.288) or the other antimicrobial agents analysed.
Sex, age and type of interventional procedure (PTC/ERC) had no predictive value for antimicrobial resistance in either the univariate or the multivariate analyses (Table 3 and 4) .
Discussion
Our data justify the use of broad-spectrum antimicrobial regimens for the empirical treatment of acute cholangitis in patients undergoing stent therapy to minimize the risk of a therapy failure before antimicrobial susceptibility testing is available. The reason for the higher incidence of antimicrobial resistance in patients undergoing stent therapy is certainly related to the fact that stent therapy involves quite a large number of hospitalizations at short intervals. It is general practice to perform stent exchanges every 3 months up to the end of stent therapy to minimize the risk of the stent clogging. 18 According to numerous studies, previous hospitalization is a risk factor for increased antimicrobial resistance.
19 -21 Antibiotic treatment and not stent therapy is undoubtedly the driving force for the development of resistance. However, the major aim of the study was to show that patients with stent therapy have a higher incidence of antimicrobial resistance compared with patients without stent therapy. Our data revealed a strong association between stent therapy and prior antibiotic treatment. Table 6 shows that the proportion of antibiotic pre-treatment is significantly higher in episodes of cholangitis with stent therapy compared with cholangitis without stent therapy (107/157 versus 25/152; P . 0.001). Due to this strong association, the two binary variables 'stent therapy' and 'antimicrobial pre-treatment' were confounders in the multivariate model. Therefore, only the variable 'antimicrobial pre-treatment' was included in the univariate analysis.
In line with these findings, the current study revealed that instrumentation of the biliary tree is associated with an increase in bacteria that are resistant to conventional antibiotic therapy ( Table 5) . As the number of times the biliary tree is subjected to procedures increases, there is a rise in antimicrobial resistance, suggesting that there should be a prophylactic adaption of antimicrobial potency for empirical treatment with increasing numbers of interventional procedures in cases of cholangitis. This relation seems to be reasonable, as the greater the number of previous interventional procedures performed, the more challenging drainage of the biliary tract can be, resulting in a greater likelihood of complications requiring antimicrobial treatment. According to the literature, the incidence of post-ERCP cholangitis ranges between 0.5% and 5.8%. 22, 23 As a result, the American Society of Gastroenterology guidelines recommend the use of antimicrobial prophylaxis prior to ERC in patients with known or suspected biliary obstruction in which there is a possibility that complete biliary drainage may not be achieved. 24 Interestingly, in the current study, the association between stent therapy and increased antimicrobial resistance was observed in both patients with malignant and with benign underlying diseases. Indeed, patients with benign underlying disease had a significantly higher susceptibility to ciprofloxacin compared with patients with a malignant cause for their cholangitis. However, the multivariate analysis revealed that the genesis of the 25 analysed the epidemiology of bacteraemia due to biliary tract infections. Ceftriaxone-resistant Enterobacteriaceae were significantly more common in patients with solid organ cancer. The differing results of our study might be explained by the high proportion of benign biliary obstructions requiring stent therapy.
The overall susceptibility rates of Enterobacteriaceae to ampicillin, ampicillin/sulbactam, ceftriaxone, ciprofloxacin/ofloxacin and co-trimoxazole were 40%, 53%, 90%, 85% and 81%, which lie within the range of current epidemiological antimicrobial resistance data in Europe. 26 -29 The major limitations of this study are its single-centre data source and the retrospective data acquisition. The development of antimicrobial resistance is influenced by local antibiotic policy, which may limit the extrapolation of local resistance data to other centres. During the observation period, there was a change in antimicrobial susceptibility testing. Ofloxacin was replaced by ciprofloxacin. Therefore, the antimicrobial susceptibility data for ciprofloxacin and ofloxacin were pooled.
In summary, stent therapy is a good surrogate marker for the increased presence of antimicrobial resistance in patients with acute cholangitis, and can be quickly and easily assessed at the time of hospital admission.
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